IVF covered by insurance ended in a live birth more often, a US claims study finds

In vitro fertilization in the United States is unusual among major medical treatments in how often patients pay for it themselves. Whether that out-of-pocket structure changes who succeeds — not just who can start — is the question behind a retrospective cohort study published in Fertility and Sterility on October 7 [s1]. The answer it gives is yes, but the reason matters more than the headline.

The study

The researchers used Optum's Clinformatics Data Mart, a large de-identified database of privately insured Americans, and identified women aged 22 to 44 who underwent IVF between 2013 and 2020 [s1]. The exposure was whether the patient's employer-sponsored insurance covered IVF [s1]. The outcomes were cumulative live birth within 2.5 years of the first cycle; pregnancy, live birth and multiple-birth rates per cycle; and the number of cycles a patient started within that 2.5-year window [s1]. All results were adjusted [s1].

What they found

Patients whose insurance covered IVF were more likely to have a baby within 2.5 years of their first cycle: 63% versus 53% for those without coverage, an adjusted odds ratio of 1.52 (95% confidence interval 1.35 to 1.73) [s1]. That is the study's central number, and it is a substantial gap.

But the per-cycle numbers were far closer. A covered cycle led to a pregnancy 53% of the time against 49% for an uncovered cycle (odds ratio 1.20, 1.09 to 1.31), and to a live birth 37% against 33% (1.17, 1.07 to 1.29) [s1]. Where the two groups diverged sharply was how many cycles they attempted: covered patients started 1.9 cycles on average within 2.5 years, uncovered patients 1.7 (count ratio 1.12, 1.08 to 1.17) [s1].

The rate of multiple births — twins and beyond, the main safety concern in IVF — was identical at 13% in both groups (odds ratio 1.04, 0.84 to 1.29) [s1]. The data span 2013 to 2020, a period over which US practice moved steadily toward transferring a single embryo at a time, which is the backdrop against which that equal multiple-birth rate should be read.

Reading the result correctly

The authors are explicit that the large cumulative advantage was "largely driven by patients with insurance coverage for IVF initiating more IVF cycles" [s1]. This is the part worth sitting with. IVF is a numbers game: a single cycle fails more often than it succeeds, and most people who eventually have a baby do so after more than one attempt. Anything that lets a patient take more shots on goal raises the odds she ends up with a child, even if each individual shot is no better.

That reframes coverage. It is not that insured embryos implant better; it is that patients who do not have to pay several thousand dollars per attempt out of pocket keep going through the cycles that cumulatively produce a birth. Uncovered patients, facing the full cost each time, are likelier to stop before the math works in their favour.

The modest per-cycle differences — 4 percentage points on pregnancy, 4 on live birth — are harder to interpret and should not be over-read. They could reflect covered patients being able to afford genetic testing, additional embryo transfers from a single retrieval, or simply differences between people whose employers offer fertility benefits and those whose do not. This is observational data, and coverage is not randomly assigned: firms that offer IVF benefits differ from those that do not, and so may their employees.

Why the multiple-birth finding counts

The identical multiple-birth rate is reassuring for a specific policy worry. One argument against mandating coverage has been that it might push patients toward transferring multiple embryos at once to maximise the chance from an expensive cycle, raising the rate of risky twin and triplet pregnancies. In this sample, coverage did not do that — consistent with the field's broad shift toward single-embryo transfer over the study period.

What to watch

The policy context is live: several US states have expanded IVF mandates, employers are adding fertility benefits, and access is an active political question. Studies like this one inform that debate, but cannot settle whether mandated coverage would reproduce these results in the broader, less uniformly insured population. Randomised evidence is not coming; the next best thing is replication across states as coverage rules change.

This article describes a single observational study and is informational only. It is not medical advice.

Sources

• [s1] Insurance Coverage for In Vitro Fertilization is Associated with Higher Live Birth Rates in a National Sample of Privately Insured Patients, Fertility and Sterility, 2026, online ahead of print, published 2026-10-07. PMID 42843704.